Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2008 Dec 1;181(11):7944-7.
doi: 10.4049/jimmunol.181.11.7944.

Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B

Affiliations
Multicenter Study

Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B

Chloe L Thio et al. J Immunol. .

Abstract

Recovery from acute hepatitis B virus (HBV) infection occurs in 95% of adult-acquired infections. A 32-bp deletion in CCR5 (CCR5Delta32), which encodes for a nonfunctional receptor, increases the likelihood of recovery. Using 181 subjects with persistent HBV infection and 316 who had recovered, we tested the hypothesis that an epistatic interaction between functional polymorphisms in RANTES (a CCR5 ligand) and CCR5 impacts recovery. Specific models designed to assess individual contributions of compound genotypes demonstrated that the only combination associated with recovery from an HBV infection was RANTES -403A with CCR5Delta32 (odds ratio 0.36, p = 0.02). Because the phenotypic consequence of -403A is reported to be higher levels of RANTES, we propose a model in which excess RANTES in combination with low CCR5 favors recovery from an HBV infection, which will require validation through functional testing.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic diagram of RANTES gene and relative location of the coding regions (black boxes), untranslated regions (hashed boxes), and polymorphisms. The RANTES haplotypes are listed below the figure.

References

    1. Lee WM. Hepatitis B virus infection. N.Engl.J.Med. 1997;337:1733–1745. - PubMed
    1. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J.Clin.Invest. 1996;97:1655–1665. - PMC - PubMed
    1. Wong MM, Fish EN. Chemokines: attractive mediators of the immune response. Semin.Immunol. 2003;15:5–14. - PubMed
    1. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367–377. - PubMed
    1. Thio CL, Astemborski J, Bashirova A, Mosbruger T, Greer S, Witt MD, Goedert JJ, Hilgartner M, Majeske A, O'Brien SJ, Thomas DL, Carrington M. Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence. J Virol. 2007;81:441–445. - PMC - PubMed

Publication types

MeSH terms